AR131577A1 - Compuestos moduladores del receptor de dopamina d3 / d2 - Google Patents

Compuestos moduladores del receptor de dopamina d3 / d2

Info

Publication number
AR131577A1
AR131577A1 ARP240100045A ARP240100045A AR131577A1 AR 131577 A1 AR131577 A1 AR 131577A1 AR P240100045 A ARP240100045 A AR P240100045A AR P240100045 A ARP240100045 A AR P240100045A AR 131577 A1 AR131577 A1 AR 131577A1
Authority
AR
Argentina
Prior art keywords
dopamine
modulating compounds
receptor modulating
formula
compounds
Prior art date
Application number
ARP240100045A
Other languages
English (en)
Spanish (es)
Inventor
Istvn Borza
Jnos Les
Blint Menczinger
Dek Szilvia Bodnrn
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of AR131577A1 publication Critical patent/AR131577A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP240100045A 2023-01-11 2024-01-09 Compuestos moduladores del receptor de dopamina d3 / d2 AR131577A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363479530P 2023-01-11 2023-01-11

Publications (1)

Publication Number Publication Date
AR131577A1 true AR131577A1 (es) 2025-04-09

Family

ID=89573273

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240100045A AR131577A1 (es) 2023-01-11 2024-01-09 Compuestos moduladores del receptor de dopamina d3 / d2

Country Status (16)

Country Link
US (2) US12168007B1 (enExample)
EP (1) EP4400495A1 (enExample)
JP (2) JP7686096B2 (enExample)
KR (2) KR102921799B1 (enExample)
CN (2) CN122427144A (enExample)
AR (1) AR131577A1 (enExample)
AU (1) AU2024208533A1 (enExample)
CL (2) CL2025002035A1 (enExample)
CO (1) CO2025010725A2 (enExample)
GE (1) GEAP202516807A (enExample)
IL (1) IL321654A (enExample)
JO (1) JOP20250164A1 (enExample)
MX (1) MX2025008101A (enExample)
PE (1) PE20260287A1 (enExample)
TW (1) TW202432139A (enExample)
WO (1) WO2024150068A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026153547A1 (zh) * 2025-01-20 2026-07-23 上海则正医药科技股份有限公司 D3/d2受体部分激动剂及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
EP1870405A1 (en) 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
JP5732453B2 (ja) 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Nh酸性化合物のプロドラッグ
WO2020156312A1 (zh) 2019-01-30 2020-08-06 江苏豪森药业集团有限公司 一种多环类衍生物调节剂、其制备方法和应用
US12617759B2 (en) 2019-10-29 2026-05-05 Shanghai Hansoh Biomedical Co., Ltd. Modifier of four-membered ring derivative, preparation method and application thereof
KR102947882B1 (ko) 2019-11-05 2026-04-03 상하이 한서 바이오메디컬 컴퍼니 리미티드 벤조티오펜 유도체 조절제, 그의 제조 방법 및 그의 용도

Also Published As

Publication number Publication date
CL2025002035A1 (es) 2025-10-03
CN120569367A (zh) 2025-08-29
EP4400495A1 (en) 2024-07-17
CO2025010725A2 (es) 2025-08-29
KR102921799B1 (ko) 2026-02-04
JP2024098972A (ja) 2024-07-24
PE20260287A1 (es) 2026-02-10
US12168007B1 (en) 2024-12-17
TW202432139A (zh) 2024-08-16
US20250049786A1 (en) 2025-02-13
KR20260019592A (ko) 2026-02-10
WO2024150068A3 (en) 2024-08-22
GEAP202516807A (en) 2025-08-25
AU2024208533A1 (en) 2025-07-10
JP7686096B2 (ja) 2025-05-30
JP2025122072A (ja) 2025-08-20
MX2025008101A (es) 2025-08-01
CL2026000558A1 (es) 2026-06-05
JOP20250164A1 (ar) 2025-07-10
IL321654A (en) 2025-08-01
KR20240112213A (ko) 2024-07-18
WO2024150068A2 (en) 2024-07-18
CN122427144A (zh) 2026-07-21

Similar Documents

Publication Publication Date Title
AR077252A1 (es) Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
UY30641A1 (es) Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones
MX2022001158A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2020006438A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1.
DOP2021000198A (es) Compuestos y su uso en el tratamiento del cáncer
MX379530B (es) Compuestos agonistas del receptor muscarínico m4.
CR20180541A (es) Inhibidores de bromodominios
MX2020006460A (es) Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
CY1120179T1 (el) Ετεροκυκλικη ενωση που περιεχει αζωτο ή αλας αυτης
CL2019001264A1 (es) Ácidos propiónicos 3-sustituidos como inhibidores de la integrina alfa v.
MX2017016344A (es) Compuestos de benzoxacepina oxazolidinona y metodos de uso.
MA39995B1 (fr) Composés destinés à traiter l'amyotrophie spinale
UY39559A (es) Compuestos y su uso
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
CL2009000445A1 (es) Compuestos derivados de piperidina 1,4 heterociclo sustituidos, procedimiento para preparar estos compuestos, composicion farmaceutica que los comprende y su uso para la terapia del dolor y el tratamiento de enfermedades como alzheimer, esquizofrenia, ansiedad y depresion.
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
CL2022001337A1 (es) Derivados de piridopirimidinona como antagonistas de ahr
CO2018007436A2 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
CO2025010725A2 (es) Compuestos moduladores de receptores de dopamina d3/d2
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MX2007003105A (es) Derivados de bencimidazol, composiciones que los contienen, sus preparaciones y sus usos i.
CL2019003467A1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
CR20240216A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
ECSP088968A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia